Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kathrin Kizina"'
Autor:
Andreas Thimm, Svenja Brakemeier, Kathrin Kizina, Juan Munoz Rosales, Benjamin Stolte, Andreas Totzeck, Cornelius Deuschl, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
Frontiers in Neurology, Vol 12 (2022)
5q-Spinal muscular atrophy (SMA) is a severely disabling inherited neuromuscular disease that progressively reduces the motor abilities of affected individuals. The approval of the antisense oligonucleotide nusinersen, which has been shown to improve
Externí odkaz:
https://doaj.org/article/724ed15c3c2a4ff6ac621eb053cf6533
Autor:
Andreas Totzeck, Elakiya Ramakrishnan, Melina Schlag, Benjamin Stolte, Kathrin Kizina, Saskia Bolz, Andreas Thimm, Mark Stettner, Julian R. Marchesi, Jan Buer, Christoph Kleinschnitz, Hedda Luise Verhasselt, Tim Hagenacker
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To
Externí odkaz:
https://doaj.org/article/db7f381540b3464b8091b6a78127b110
Autor:
Saskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, Elisabeth Livingstone, Benjamin Stolte, Andreas Thimm, Kathrin Kizina, Selma Ugurel, Christoph Kleinschnitz, Martin Glas, Lisa Zimmer, Tim Hagenacker
Publikováno v:
eNeurologicalSci, Vol 22, Iss , Pp 100324- (2021)
Background: Checkpoint inhibitors show impressive and durable responses in various cancer types and provide new avenues for cancer immunotherapy. However, these drugs have a variety of adverse events. Common autoimmune-related adverse effects include
Externí odkaz:
https://doaj.org/article/14cf8712fac74c8cbdc19a5656d74355
Autor:
Kathrin Kizina, Yakup Akkaya, Daniel Jokisch, Benjamin Stolte, Andreas Totzeck, Juan Munoz-Rosales, Andreas Thimm, Saskia Bolz, Svenja Brakemeier, Refik Pul, Derya Aslan, Jana Hackert, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
Brain Sciences, Vol 11, Iss 9, p 1184 (2021)
In previous studies, a below-average, average, or above-average intelligence quotient (IQ) in children with SMA was detected but, aside from a severe physical disability, the cognitive performance of adult SMA patients has not yet been evaluated. The
Externí odkaz:
https://doaj.org/article/590b21c9a2b64ccfa46dbf2414b53e94
Autor:
Svenja Brakemeier, Benjamin Stolte, Andreas Thimm, Kathrin Kizina, Andreas Totzeck, Juan Munoz-Rosales, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
Brain Sciences, Vol 11, Iss 9, p 1244 (2021)
The antisense oligonucleotide nusinersen has been shown to improve trunk and limb motor function in patients with spinal muscular atrophy (SMA). Bulbar dysfunction, which is regularly present in SMA, is not captured by standard motor scores, and vali
Externí odkaz:
https://doaj.org/article/af35b9c1d58e4494831d81ef69f773a7
Autor:
Kathrin Kizina, Benjamin Stolte, Andreas Totzeck, Saskia Bolz, Michael Fleischer, Christoph Mönninghoff, Nika Guberina, Denise Oldenburg, Michael Forsting, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background: Spinal muscular atrophy (SMA) is a genetic disorder that leads to progressive tetraparesis. Nusinersen is the first approved drug for the treatment of SMA and is administered via intrathecal injections. Neuromyopathic scoliosis and spondy
Externí odkaz:
https://doaj.org/article/994d19065df64b09a983806b7e73a73a
Autor:
Benjamin Stolte, Andreas Totzeck, Kathrin Kizina, Saskia Bolz, Lena Pietruck, Christoph Mönninghoff, Nika Guberina, Denise Oldenburg, Michael Forsting, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: Nusinersen is an intrathecally administered antisense oligonucleotide (ASO) and the first approved drug for the treatment of spinal muscular atrophy (SMA). However, progressive neuromyopathic scoliosis and the presence of spondylodesis ca
Externí odkaz:
https://doaj.org/article/2d9cd558435a4764ae2aaa9e02533047
Autor:
Andreas Totzeck, Benjamin Stolte, Kathrin Kizina, Saskia Bolz, Melina Schlag, Andreas Thimm, Christoph Kleinschnitz, Tim Hagenacker
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 21, p 5397 (2019)
Nusinersen is the first approved drug for the treatment of spinal muscular atrophy (SMA). Treatment of SMA with nusinersen is based on a fixed dosing regimen. For other motoneuron diseases, such as amyotrophic lateral sclerosis (ALS), biomarkers are
Externí odkaz:
https://doaj.org/article/0763047be6b041a0b442ed97e738551c
Autor:
Kathrin Kizina, Bernd Wagner, Christoph Kleinschnitz, Andreas Totzeck, Benjamin Stolte, Michael Nonnemacher, Saskia Bolz, Cornelius Deuschl, Tim Hagenacker, Andreas Thimm
Publikováno v:
Journal of Neurology
Background Nusinersen is an intrathecally administered antisense oligonucleotide (ASO) that improves motor function in patients with spinal muscular atrophy (SMA). In addition to efficacy, the safety of a therapy is the decisive factor for the succes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee75b3276b1df994f903fc019ce87a9
https://doi.org/10.1007/s00415-021-10569-8
https://doi.org/10.1007/s00415-021-10569-8
Autor:
Andreas, Totzeck, Elakiya, Ramakrishnan, Melina, Schlag, Benjamin, Stolte, Kathrin, Kizina, Saskia, Bolz, Andreas, Thimm, Mark, Stettner, Julian R, Marchesi, Jan, Buer, Christoph, Kleinschnitz, Hedda Luise, Verhasselt, Tim, Hagenacker
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders
Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cde9c37dca139df7ed1daf0216efb9dd
https://duepublico2.uni-due.de/receive/duepublico_mods_00076185
https://duepublico2.uni-due.de/receive/duepublico_mods_00076185
